
Patients with multiple myeloma (MM) often face relapsed/refractory disease despite initial responses to firstline treatment. B-cell maturation antigen (BCMA) has emerged as a promising target for the treatment of MM.
Belantamab mafodotin is an experimental antibody-drug conjugate that targets BCMA that initially showed activity as a single agent in relapsed/refractory MM. In the multicenter, phase II, ongoing DREAMM-2 study, 31% of patients (n=30) who received belantamab mafodotin 2.5 mg/kg and 34% (n=34) who received belantamab mafodotin 3.4 mg/kg achieved an overall response, including three complete responses.
Paul G. Richardson, MD, the clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and RJ Corman Professor of Medicine at Harvard Medical School, discussed the outcomes of the DREAMM-2 study and how he sees belantamab mafodotin impacting the MM treatment landscape.